KeifeRx seeks to leverage mechanisms of action inherent to TKIs which thus far have been underexplored: the ability to penetrate the brain, induce autophagy, and enable the bulk disposal of disease-causing toxic proteins to treat neurodegenerative diseases, and the ability to target mast cells and simultaneously modulate peripheral and central immunity, providing therapeutic potential for an array of inflammatory diseases.
These properties offer the potential to significantly improve upon current neurodegenerative and immune disease treatments, which are primarily palliative and offer minimal and temporary benefits due to their inability to adequately eliminate toxic proteins and mitigate inflammation.
These properties offer the potential to significantly improve upon current neurodegenerative and immune disease treatments, which are primarily palliative and offer minimal and temporary benefits due to their inability to adequately eliminate toxic proteins and mitigate inflammation.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Virginia
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
KFRX01
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
